Perspective · 10 Sep 2026
Conference abstractPublished 22 Oct 2012
Soypeptide lunasin as an immune modulating agent: Implication in cancer immunotherapy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Cytokine immunotherapy enhances the anti-tumor immunity and is now part of the therapeutic armamentarium for cancer treatment. We have previously reported that heavily-treated lymphoma patients have acquired deficiency of Signal Transducer and Activator of Transcription 4 (STAT4), which results in defective production of IFNÃ?³ following IL-12 immunotherapy. With the goal of further improvement in cytokine immunotherapy, we examined the effects of a soybean peptide called lunasin that exhibits immunostimulatory effects. Adding lunasin to IL-12- or IL-2-stimulated NK cell cultures demonstrated synergistic effects in the induction of IFNG and genes involved in cytotoxicity. The combination of lunasin and cytokine cocktails (IL-12 plus IL-2) was capable of restoring IFNÃ?³ production by NK cells in post-transplant lymphoma patients who have defective cytokine responses. In addition, NK cells stimulated with lunasin plus cytokines have higher tumoricidal activity than those stimulated with cytokine alone using in vitro and in vivo tumor models. The underlying mechanism responsible for the effects of lunasin on NK cells is likely due to epigenetic modulation on target gene loci. Thus, the combination of lunasin and selected cytokine (designated as lunakine) is superior to cytokine alone and could be a novel therapeutic to improve the efficacy of cytokine immunotherapy.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical and Cellular Immunology.
Commentary · 22 Jul 2026
From Bench to Bedside: Reframing the CXCL13/CXCR5 Axis as a Non-Redundant Organizer of Protective Pulmonary Immunity in COVID-19
Commentary · 17 Jul 2026
CD5L:p40, a third wheel to IL-12 and IL-23 biology?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Cellular Immunology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Charles J. Malemud”
